Drug intelligence / Profile preview

GamLPV

Development stage: Unknown
Lead developer: Gamaleya Center
Modality: Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intranasal

Overview

GamLPV is a live attenuated intranasal vaccine candidate developed for the prevention of pertussis (whooping cough). It is designed to be administered via the nasal route, mimicking natural infection and aiming to induce both mucosal and systemic immunity against Bordetella pertussis, the causative agent of whooping cough. The vaccine is currently being evaluated in clinical trials for its safety and immunogenicity[1].

Brand names: GamLPV
Other names: GamLPV

Beyond the preview

Go deeper on GamLPV.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GamLPV.

Explore the full profile